MetLife director reports stock compensation award and holdings update

MetLife, Inc. director reported receiving common stock as part of non-management director compensation on 01/02/2026.

Rhea-AI Filing Summary

MetLife, Inc. director reported receiving common stock as part of non-management director compensation on 01/02/2026. The filing shows an acquisition of 639 shares of MetLife common stock at $80.32 per share, bringing the director's directly held position to 45,415 shares. An additional 10 shares are reported as indirectly owned through the MetLife Policyholder Trust.

The company’s arrangements pay a portion of non-management director retainer fees in MetLife common stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Insider Trade Summary

Grant/Award: 639 shares

Grant/Award 2 txns

Insider Kennard William E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	639	$80.32	$51K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 45,415 shares (Direct); Common Stock — 10 shares (Indirect, By the MetLife Policyholder Trust)

Footnotes (2)

1. F1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
2. F2. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transaction did MetLife (MET) disclose in this filing?

The filing reports that a MetLife non-management director acquired 639 shares of MetLife common stock on 01/02/2026 at a price of $80.32 per share as part of director compensation.

How many MetLife (MET) shares does the director beneficially own after this transaction?

After the reported transaction, the director beneficially owns 45,415 shares of MetLife common stock directly and 10 shares indirectly through the MetLife Policyholder Trust.

Why did the MetLife (MET) director receive shares, according to the filing?

The filing explains that MetLife’s non-management director compensation arrangements pay a portion of retainer fees in MetLife common stock, and the director received shares under this program.

Did the MetLife (MET) director defer the stock received in this transaction?

Yes. The director elected to defer receipt of the shares under the MetLife Deferred Compensation Plan for Non-Management Directors, as described in the explanation of responses.

What are the indirectly owned MetLife (MET) shares mentioned in the filing?

The filing notes 10 shares are held indirectly by the director in the MetLife Policyholder Trust, which holds common stock allocated to eligible policyholders of Metropolitan Life Insurance Company.

What is the director’s relationship to MetLife (MET) as identified in the filing?

The individual is identified as a director of MetLife, Inc. and the form is filed by one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 04:11 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennard William E

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A(1)		639	A	$80.32	45,415	D
Common Stock								10	I	By the MetLife Policyholder Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

2. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.